European Commission Expands GSK's RSV Vaccine Arexvy to Adults Aged 18 and Above
GSK’s RSV vaccine Arexvy receives European approval for adults aged 18 plus, marking a major expansion in protection against RSV-related respiratory illness across the region.
RSV Vaccine | 28/01/2026 | By News Bureau
ACON Launches FDA-Cleared Flowflex Plus 4-in-1 Home Test for RSV, Flu and Covid, Including Infants
Acon Laboratories has launched the first FDA-cleared 4-in-1 home test detecting RSV, Flu A, Flu B and Covid-19, approved for adults and children as young as six months.
RSV Vaccine | 27/01/2026 | By News Bureau | 164
FDA to Review GSK's Application to Expand Arexvy RSV Vaccine Use
The US Food and Drug Administration (FDA) has accepted to review GlaxoSmithKline (GSK)'s application to expand the use of its RSV vaccine, Arexvy, to include adults aged 18–49 who are at increased risk.
RSV Vaccine | 16/07/2025 | By Dineshwori | 228
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy